NDAINJECTIONINJECTABLE
Approved
Nov 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
16
Data completeness
3/8 — Basic
MITOZYTREX (mitomycin) by Glaukos is alkylating activity [moa]. First approved in 2002.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MITOZYTREX is a mitomycin-based injectable chemotherapy agent that functions as an alkylating agent to inhibit DNA synthesis and cell division. It is indicated for various cancers and is administered via injection. The drug represents a mature chemotherapy backbone in oncology with broad historical use across multiple tumor types.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), signaling a stable but non-growth commercial environment with potential consolidation of smaller brand teams.
Mechanism of Action
Alkylating Activity
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (16)
Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy
Started Sep 2022
201 enrolled
Colorectal CancerChemotherapy EffectSurgery+2 more
Safety and Efficacy of an Ab Interno Gelatin Stent (XEN63) With or Without Mitomycin C
Started Nov 2020
30 enrolled
Glaucoma, Open-Angle
Ab Interno Gelatin Stent With Mitomycin C Using Targeted Supra-tenon's Placement
Started Jun 2019
142 enrolled
Glaucoma
Comparing Preoperative Injection of Mitomycin-C vs. Intraoperative Injection of Mitomycin-C vs. Topical Application of Mitomycin-C (Conventional Use) in Trabeculectomy
Started Mar 2019
19 enrolled
Glaucoma Open-Angle PrimaryGlaucomaOpen Angle Glaucoma+1 more
A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study
Started Jan 2019
50 enrolled
Urinary Bladder CancerInvasive Bladder Cancer
Worked on MITOZYTREX at Glaukos? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.